GlassScriptPhysician profile
Mark R Hanudel
NPI 1891956710
$23,663.62
in general payments reported to CMS, 2019-2025
11 companies · $8,030 in 2025
The $8,030 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $2,678 · 2021: $3,483 · 2022: $6,510 · 2023: $1,500 · 2024: $1,186 · 2025: $8,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,129 · Travel and Lodging: $1,340 · Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,128.75 |
| Travel and Lodging | $1,340.44 |
| Food and Beverage | $247.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $8,010.00 | 2022-2023 | |
| Novo Nordisk INC | $7,856.44 | 2024-2025 | Rivfloza |
| Akebia Therapeutics INC | $3,145.45 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,152.50 | 2020 | |
| C. R. Bard, INC. & Subsidiaries | $1,058.33 | 2020-2021 | |
| Zoll Medical Corporation | $1,050.00 | 2024 | Defibrillator |
| Alexion Pharmaceuticals, INC. | $207.36 | 2024-2025 | Ultomiris |
| Fresenius USA Marketing, INC. | $80.80 | 2019 | |
| Alnylam Pharmaceuticals INC. | $53.39 | 2024 | Oxlumo, Givlaari |
| Apellis Pharmaceuticals, INC. | $27.13 | 2025 | Empaveli |
| Novartis Pharmaceuticals Corporation | $22.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hanudel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.